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ABSTRACT
Total body irradiation (TBI) is an important part of bone marrow transplantation conditioning regimens. In
TBI, dose escalation is difficult, because of associated normal organ toxicities. A method to deliver a more
targeted dose of TBI preferentially to sites of greatest tumor burden is needed to reduce the dose to normal
organs, reduce toxicities, and permit dose escalation. The purpose of this study was to evaluate, through a
dosimetric analysis, the potential advantages and feasibility of selectively delivering targeted myeloablative
doses of radiation to bone and marrow using a recently developed image-guided tomographic intensity-
modulated radiation therapy delivery system (helical tomotherapy). Whole-body computed tomography data-
sets from 3 patients, age 5, 20, and 53 years, were used for treatment planning studies to evaluate 2 targeted
TBI strategies: total marrow irradiation (TMI), in which the target region was defined as the skeletal bone, and
total marrow and lymphoid irradiation (TMLI), in which the target regions were defined as bone, major lymph
node chains, liver, spleen, and sanctuary sites, such as brain. Organ doses and dose distributions were compared
with those in conventional TBI. A 1.7- to 7.5-fold reduction in median organ doses was observed with TMI and
TMLI compared with conventional TBI. With this more targeted approach, a dose-volume histogram analysis
predicted the potential to escalate the dose to bone (and containing marrow) up to 20 Gy, while maintaining
doses to normal organs at lower levels than in conventional TBI to 12 Gy. Results were similar for the adult
and pediatric patients, indicating that this form of targeted TBI will be applicable to most patients regardless
of frame size. TMI to 10 Gy was delivered as part of a tandem transplant regimen to the 53-year-old patient
with multiple myeloma. Clinical results confirmed the treatment planning predictions. After TMI, the patient
experienced the expected blood count nadir, followed by successful engraftment. Grade 2 nausea and grade 1
emesis occurred only briefly on day 2 of TMI. Skin erythema, oral mucositis, esophagitis, and enteritis were not
observed. This report demonstrates the feasibility and potential dosimetric advantages of selectively delivering
myeloablative doses of radiation to bone and marrow using an image-guided tomographic intensity-modulated
radiation therapy delivery system. Organ doses are substantially lower than those associated with standard TBI
and predict the potential to significantly reduce associated toxicities and allow for dose escalation. The results
also suggest that this form of targeted TBI may have potential advantages over other forms of targeted TBI,
such as radioimmunotherapy or bone-seeking radionuclide therapy. Ongoing clinical trials will define the
maximum TMI and TMLI doses achievable and define the potential advantages and limitations of this new
approach for patients undergoing hematopoietic stem cell transplantation.
© 2006 American Society for Blood and Marrow Transplantation
KEY WORDS
Total marrow irradiation ● Total body irradiation ● Helical tomotherapy ● Multiple myeloma
06
It
g
p
e
g
a
p
t
t
c
a
t
r
g
m
c
m
t
i
m
b
d
p
l
i
p
p
d
s
t
d
n
i
d
g
6
a
c
d
m
[
c
f
o
d
b
t
M
f
w
l
a
T
t
m
b
d
r
a
[
t
G
G
m
T
l
a
c
t
l
c
o
L
o
t
e
(
b
c
o
i
m
s
c
l
h
a
T
t
I
t
t
o
w
D
a
TS
P
Targeted TBI With Tomotherapy
BNTRODUCTION
Total body irradiation (TBI) has played an impor-
ant role in conditioning regimens for patients under-
oing hematopoietic stem cell transplantation. The
rimary reasons for using TBI include tumor cell
radication and immunosuppression to allow for en-
raftment of donor marrow. In addition, TBI, acting
s a form of “systemic radiotherapy,” potentially com-
lements high-dose systemic chemotherapy, providing
herapy to sanctuary sites not easily reached by chemo-
herapy drugs and provides another mechanism of tumor
ell kill against chemotherapy-resistant cell clones.
Historically, TBI has been primarily used as part of
dose-intensive myeloablative regimen. Clinical efforts
o further intensify TBI dose have produced decreased
elapsed rates in patients with myeloid leukemias under-
oing allogeneic transplantation [1,2]. However, treat-
ent-related morbidity and mortality have also in-
reased, negating any potential advantage for survival. A
ore targeted form of TBI is clearly needed to reduce
he dose to normal organs relative to tumor, which would
mprove the therapeutic ratio of this important treatment
odality and allow for further dose escalation [3].
Signiﬁcant technological advances have recently
een introduced in the radiation oncology clinic. By
elivering therapy from multiple directions using multi-
le segmented or modulated beamlets, intensity-modu-
ated radiation therapy (IMRT) allows for greater sculpt-
ng of radiation doses to ﬁt the unique shape of each
atient’s tumor, optimizing radiation delivery to com-
lex volumes and regions of the body. As a result, the
ose to adjacent critical organs is minimized, reducing
ide effects and allowing for dose escalation to the
umor, thus improving outcomes [4].
Helical tomotherapy (HT) is a radiation therapy
elivery device that represents an integration of tech-
ological advances in computed tomography (CT)
mage-guided radiotherapy and IMRT, permitting the
elivery of image-guided IMRT in a helical tomo-
raphic fashion. The maximum target size possible is
0 cm wide  approximately 160 cm long [5]. The
dvent of HT therefore brings for the ﬁrst time to the
linic the potential to deliver highly conforming dose
istributions to large complex target shapes while si-
ultaneously avoiding doses to critical normal organs
6-12], making it an attractive option for the delivery of
onformal targeted TBI selectively to bone and marrow.
In this article we report studies demonstrating the
easibility and advantages of targeted TBI using HT
ver conventional TBI, with the goal of increasing
ose conformity to anatomic areas of greatest tumor
urden, reducing dose to normal organs, decreasing
oxicities, and permitting dose escalation to tumors.
upported in part by National Institutes of Health grants CA33572 and
p50 CA30206-23.
B&MTATERIALS AND METHODS
For the initial studies, whole-body CT datasets
rom a 20-year-old adult female and a 5-year-old girl
ere used. Each patient had a diagnosis of acute myeloid
eukemia (AML) and underwent CT scanning as part of
standard protocol at this institution for conventional
BI planning before hematopoietic stem cell transplan-
ation. The following organs were contoured for treat-
ent planning: lungs, liver, spleen, heart, small and large
owel, kidneys, orbits, lenses, brain, esophagus, blad-
er, parotid glands, oral cavity, stomach, breasts, ova-
ies, major lymph node chains, and bone.
Conventional TBI treatment at our institution is
n adaptation of the method published by Shank et al.
13]. The patient is treated at an extended distance in
he standing position. A total of 10 treatments of 1.2
y are delivered over 4 days, for a total of 12 to 13.2
y. On days 1, 2, and 3, the patient receives 3 treat-
ents with a 4- to 5-hour interval between fractions.
he remaining treatments are given on day 4. The
ungs are shielded with 50% transmission blocks for
ll treatments, and the dose to the chest wall and rib
age underlying the block is supplemented with elec-
ron beam radiotherapy of appropriate energy to de-
iver 3 Gy per day, for a total of 6 Gy. For this study,
onventional TBI dose distributions were simulated
n the CMS XiO treatment planning system (St.
ouis, MO).
TBI dose distributions using HT were simulated
n the TomoTherapy Hi-Art treatment planning sys-
em. Two targeted TBI treatment strategies were
valuated. In the ﬁrst strategy, total marrow irradiation
TMI), the target region is deﬁned as the skeletal
one. The TMI approach is applicable as part of a
onditioning regimen for multiple myeloma. The sec-
nd targeted TBI strategy, total marrow and lymphoid
rradiation (TMLI), deﬁnes the target regions as bone,
ajor lymph node chains, liver, spleen, and sanctuary
ites, such as brain. TMLI is of interest as part of a
onditioning regimen for patients with myeloid and
ymphoid leukemias, for example.
Details of the Hi-Art treatment planning system
ave been published previously [6]. For these studies,
25-mm slice thickness and a pitch of 0.35 were used.
he pitch is deﬁned as the distance that the table
ravels in 1 gantry rotation divided by slice thickness.
n all cases for this study, a minimum of 80% of the
arget volume was to receive the prescribed dose, with
he primary objective being to reduce the normal
rgan D50 (median dose) and D90 (maximum dose of
hich 90% of the organ receives) to a minimum.
ose-volume histograms (DVHs) were obtained for
ll contoured organs and the target volumes.
DVH analysis was used to compare conventional
BI plans with TMI and TMLI plans. DVHs, which
lot organ volume as a function of dose received, have
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3een shown to be useful in predicting radiation toxic-
ty [14]. For conventional TBI, DVHs for normal
rgans are nearly identical for the target region, as
hown in Figure 1A. The goal of designing targeted
MI and TMLI using HT was to essentially shift the
ritical organ DVH down and to the left while main-
aining the full dose to the entire target region, as
hown in Figure 1B.
igure 2. Color wash of a TMI tomotherapy plan to a prescribed do
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igure 1.Hypothetical DVHs for tumor and normal organ. (A) Th
his is comparable to conventional TBI. (B) DVHs for targeted RT
he tumor DVH is unchanged. However, the critical organ DVH is
ase, only approximately 20% of the organ receives 2Gy.ral cavity, thyroid, lungs, heart, soft tissue, and gastrointestinal tract is se
08ESULTS
MI versus Conventional TBI
Initial analysis compared conventional TBI and
MI delivered by HT in the 20-year-old female with
ML. Figure 2 shows the dose distribution color wash
f this TMI plan and demonstrates sculpting of the
ull dose to skeletal bone/marrow with avoidance of
Gy in a 20-year-old adult female. Relative sparing of dose to brain,
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umor. The full dose is still delivered to the entire tumor; as a result,
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Targeted TBI With Tomotherapy
Bung, heart, gastrointestinal tract, thyroid, breast, and
ther soft tissues. Figure 3 shows organ DVHs for
onventional TBI to 12 Gy. As expected, for all nor-
al organs except lung, nearly the entire organ re-
eives the full dose. With partial lung shielding, the
VHs for lung are shifted to the left, although ap-
roximately 40% of the lung volume still receives 10
y or more and 100% of the lung volume receives
lose to 6 Gy or more. For comparison, Figure 4
hows DVHs for the same patient receiving 12 Gy
MI. All normal organ DVHs are shifted to the left,
hile the target region continues to receive full dose.
able 1 reports median doses to normal organs for the
plans, showing that a 1.7- to 7.5-fold reduction in
edian dose is achieved with TMI compared with
onventional TBI.
igure 3. DVHs for major normal organs for the case of a 20-year-
ld female undergoing conventional TBI. Except for lung, the full
ose is delivered to almost the entire normal organ. Partial blocking
esults in some dosage reduction to the lung.
igure 4. DVHs for major normal organs for the case of a 20-year
rgans are shifted to the left of the target (bone) DVH and to the
o a large volume of each normal organ.
B&MTose Escalation of Targeted TMI to 20 Gy
To evaluate the potential for dose escalation using
his approach, treatment plans for TMI to 20 Gy were
ext evaluated and compared with TMI to 12 Gy and
onventional TBI to 12 Gy for the same 20-year-old
emale patient. Median organ doses for TMI 20 Gy are
till less than for conventional TBI 12 Gy (Table 2).
ecause pneumonitis is a major dose-limiting toxicity
f conventional TBI, lung DVH curves for the various
lans were compared (Figure 5). The TMI 20 Gy
urve shifts to the right of the TMI 12 Gy curve, but
ll portions of the TMI 20 Gy curve remain to the left
f those for conventional TBI 12 Gy, indicating that
ung doses are lower for TMI up to 20 Gy than for
onventional TBI to 12 Gy.
male undergoing TMI delivered by HT. The DVHs for all major
he DVHs for conventional TBI (Figure 3), indicating lower doses
able 1. Comparison of Median Doses (Gy) to Normal Organs for
MI versus TBI to 12 Gy
Organ
TMI 12
Gy
TBI 12
Gy
Ratio of TBI/TMI
Median Doses
ungs 4.3 8.8 2.1
sophagus 3.9 12.4 3.2
iver 6.0 12.3 2.1
idneys 5.6 12.2 2.2
owel 3.5 12.3 3.5
ladder 7.0 12.4 1.8
yes 6.6 11.3 1.7
arotids 3.9 11.8 3.0
ral cavity 2.2 11.8 5.4
tomach 3.1 12.2 3.9
varies 4.3 12.3 2.9
reasts 6.9 11.5 1.7
eart 6.2 12.1 2.0
hyroid 3.7 12.1 3.3
rain 4.0 12.0 3.0
ens 1.5 11.3 7.5-old fe
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3MLI versus Conventional TBI
Treatment plans were also developed for the same
0-year-old female patient treated with TMLI, where
he target region was expanded to include not only
keletal bone/marrow, but also liver, spleen, major
ymph node chains, and sanctuary sites such as brain.
igure 6 displays median doses to normal organs for
MLI to 13.2 Gy compared with TMI to 13.2 Gy and
onventional TBI to 13.2 Gy. Also shown are organ
oses for a plan in which just the skeletal bone/mar-
ow compartment is treated to 15.8 Gy while the dose
o liver, spleen, and brain remains at 13.2 Gy. Adding
iver, spleen, and brain as target regions with TMLI
oes not signiﬁcantly increase median organ doses
ompared with TMI, and median doses remain well
elow those of conventional TBI to 13.2 Gy.
ose Escalation of TMLI to 20 Gy
Finally, treatment plans were developed for the
ame 20-year-old patient treated with TMLI, with
able 2. Median Doses (Gy) to Normal Organs for TMI to 12 Gy,
MI to 20 Gy, and TBI to 12 Gy
Organ TMI 12 Gy TMI 20 Gy TBI 12 Gy
ungs 4.3 6.8 8.84
sophagus 3.9 5.6 12.4
iver 6.0 8.7 12.3
idneys 5.6 8.7 12.2
owel 3.5 5.0 12.3
ladder 7.0 7.4 12.4
yes 6.6 7.0 11.3
arotids 3.9 4.8 11.8
ral cavity 2.2 3.0 11.8
tomach 3.1 5.0 12.2
varies 4.3 6.0 12.3
reasts 6.9 8.7 11.5
eart 6.2 6.4 12.1
hyroid 3.7 4.9 12.1
rain 4.0 7.9 12.0
ens 1.5 1.9 11.3
0 
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igure 5. Lung DVHs for the case of a 20-year-old female treated
ith TMI 12 Gy, TMI 20 Gy and conventional TBI 12 Gy. The
VHs for TMI 12 or 20 Gy remains to the left of TBI 12 Gy,dredicting potentially less pulmonary toxicity compared with TBI.
10he TMI compartment escalated to 20 Gy while
iver, spleen, and brain were treated to 12 Gy and all
ther organs were treated as avoidance structures.
igure 7 displays DVH curves for critical organs
reated by these 2 plans. For this TMLI plan, all
VH curves remain well to the left of conventional
BI DVH curves, predicting the ability to deliver
p to 20 Gy to the marrow compartment with
omparable or reduced risks of mucositis, esophagi-
is, enteritis, pneumonitis, nephropathy, and cardio-
yopathy.
MLI in a Pediatric Patient
TMLI treatment plans were also developed us-
ng a CT dataset from a 5-year-old girl. This patient
emonstrated similar shifting of DVH curves for all
ritical organs well to the left of that for the target
egions (data not shown), indicating that targeted
BI with HT will also be feasible in a pediatric
opulation.
elivery of TMI to a Patient with
ultiple Myeloma
Based on the foregoing results supporting the
dvantages of TMI, a phase I clinical trial evaluating
MI in patients with multiple myeloma was initi-
ted at our institution. Details of this ongoing trial
ill be the subject of a separate publication. Brieﬂy,
atients with stage I–III multiple myeloma who
emonstrate response or stable disease after chemo-
herapy undergo tandem high-dose therapy with
eripheral blood progenitor cell (PBPC) support.
he ﬁrst high-dose therapy consists of melphalan,
ollowed a minimum of 6 weeks later by TMI. In
his trial, the initial dose level of TMI is 10 Gy,
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Blans to escalate TMI dose for each cohort of pa-
ients in accordance with a conventional phase I
rial design.
The ﬁrst patient in this study was a 53-year-old
oman who presented with stage I-A IgG multiple
yeloma. After responding to decadron and thalido-
ide therapy, the patient then received intravenous
elphalan 100 mg/m2 on days 2 and 1, with re-
nfusion of PBPC cells on day 0. The white blood cell
ount nadir was at day 5, and absolute neutrophil
ounts recovered to 500/L by day 13. Platelet nadir
as at day 8, with cessation of platelet transfusions
eached by day 9. Twelve weeks later TMI was per-
ormed, delivering 2 Gy/day from days6 through2,
or a total of 10 Gy. Treatments were provided with
he patient maintained in the supine position using
tandard immobilization techniques. The current HT
reatment table has a maximum travel of 1.6 m; there-
ore, anterior and posterior (AP/PA) open ﬁelds on a
onventional linear accelerator were matched to the
nferior border of the HT ﬁeld to treat the lower
xtremities. The approximate duration of the TMI
reatment was 50 minutes of beam-on time to deliver
2-Gy fraction.
Median organ doses for this patient’s TMI therapy
re given in Table 3. Figure 8 displays target and
ritical organ DVHs (A) and dose distribution color
ashes (B), which are comparable to those seen in the
reclinical studies. On day 0, PBPCs were reinfused.
hite blood cell count nadir (0.2 K/L) was at day 3,
nd absolute neutrophil counts recovered to 500/L
sgnuL
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igure 7. DVHs for critical normal organs in a 20-year-old female
rain, skull, liver, ribs, spleen, and major lymph node chains) compa
eft of those for TBI, predicting that the marrow compartment cany day 10. Platelet nadir (14 K/L) was at day 5, with
B&MTessation of platelet transfusions reached by day 11.
he patient experienced only a single brief episode of
rade 2 nausea and grade 1 emesis on day 2 of TMI,
hich was controlled with antiemetics. She experi-
nced no further nausea during the rest of the week
hile receiving prophylactic antiemetics. At 2 weeks,
he experienced partial alopecia. Skin erythema, oral
ucositis, esophagitis, and diarrhea were not ob-
erved.
syendiK
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0
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)yG( esoD
d with TMLI (20 Gy to bone/marrow compartment and 12 Gy to
h conventional TBI to 12 Gy. DVHs for TMLI remain well to the
alated to 20 Gy with no signiﬁcant increase in organ toxicity.
able 3. Median Organ Doses Determined From Treatment Plans
or the 53-Year-Old Female With Multiple Myeloma Treated
ith 10-Gy TMI
Organ
TMI 10
Gy
TBI 10
Gy
Ratio of TBI/TMI
Median Doses
ungs 4.4 8.3 1.89
sophagus 3.7 10.2 2.76
iver 6.0 10.2 1.70
idneys 6.0 10.0 1.67
owel 4.0 10.4 2.60
ladder 6.0 10.3 1.72
yes 5.4 10.0 1.85
arotids 3.8 10.5 2.76
ral cavity 2.2 10.4 4.73
tomach 3.8 10.0 2.63
varies 5.3 10.3 1.94
reasts 6.1 10.3 1.69
eart 4.8 9.9 2.06
hyroid 2.3 10.4 4.52
rain 4.7 10.3 2.19
ens 1.3 9.0 6.92
MI organ doses are compared with median doses from a 10-Gy0
02
04
06
08
001
2
4
6
8
01
treate
red witstandard TBI plan in the same patient.
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3ISCUSSION
TBI remains a critical aspect of conditioning reg-
mens for patients undergoing hematopoietic stem cell
ransplantation for hematologic malignancies. The
eneﬁts of TBI are well documented and can include
umoricidal effects and immunosuppression to facili-
ate engraftment of donor marrow. Toxicities from
BI, which is often delivered with chemotherapy, are
lso well described and include mucositis, esophagitis,
erostomia [15], nausea, vomiting, enteritis [16], pneu-
onitis [17,18], veno-occlusive disease [19], hypothy-
oidism [20], nephropathy [21], and cataract forma-
ion [22].
To improve outcomes, 2 randomized trials have
valuated the effects of increasing the dose of fraction-
ted TBI. A total of 71 patients with AML in ﬁrst
emission were randomized to cyclophosphamide and
2 Gy (2 Gy/day  6) or 15.75 Gy (2.25 Gy/day  7)
f TBI. The group receiving the higher TBI dose had
3-year relapse rate of 12%, signiﬁcantly lower than
he 35% rate for the group receiving the lower TBI
ose (P  .06) [2]. The same group of investigators
arried out a similar randomized study of 57 patients
ith chronic myeloid leukemia in the chronic phase.
he 15.75-Gy group had a 4-year relapse rate of 0%,
ompared with a rate of 25% for the 12-Gy group
P  .008) [1]. However, in both studies survival was
ot improved with higher TBI doses, because of an
ncrease in treatment-related mortality. These studies
uggest that modest increases in TBI dose can result in
clinically important reduction in relapse rate, but the
easibility of this strategy is limited by an associated
igure 8. (A) DVHs for major normal organs for the ﬁrst patient tr
or all major organs are shifted to the left of the target (bone) DVH
ose distribution color wash of the same patient.ncrease in toxicities. This has prompted efforts to t
12evelop a more targeted form of TBI that can reduce
oxicities and allow for dose escalation [3].
Rapid technologic advances have resulted in the
bility to deliver radiotherapy with greater precision at
ower doses to adjacent critical organs. HT (commer-
ially available as the TomoTherapy HiArt system) is
n FDA-approved radiation therapy delivery device
hat represents an integration of technological ad-
ances in CT image-guided radiotherapy and IMRT.
peciﬁcally, a 6-MV linear accelerator is mounted on a
T ring gantry and rotates around the patient as the
atient translates through the ring. The 40-cm-wide
reatment fan beam is segmented using a 64-leaf binary
ollimator. The minimum beamlet size is 5 6 mm; the
aximum couch travel is 160 cm. The maximum target
ize possible is approximately 60 cm wide  approxi-
ately 160 cm long [5]. This is substantially greater
overage than that afforded by linear accelerator–
ased IMRT systems, which have a maximum target
ength of approximately 15-20 cm. Thus HT allows
he delivery of highly conforming dose distributions
o large complex target shapes while simultaneously
voiding doses to critical normal organs [6-12], mak-
ng it an attractive option for the delivery of conformal
argeted TBI. Additional dose conformality is achieved
y having beamlets target from 360 degrees, compared
ith the 5-9 beam angles used by traditional IMRT
ystems.
In this study, median organ dose and dose volume
istograms were used to compare different TBI sce-
arios, because the likelihood of radiation toxicity for a
iven organ is a function of both the total dose [23] and
ith TMI delivered by HT. Target dose was 1000 cGy. The DVHs
arable to what is seen with the initial simulated case (Figure 4). (B)eated w
, comphe volume of the organ receiving that dose [14,24-26].
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Targeted TBI With Tomotherapy
Bherefore, toxicity can be substantially reduced by
imiting the volume of each organ receiving tolerance
oses. DVHs have been shown to be a predictive tool
or radiation-related toxicity [14,24-26].
Results from these studies clearly illustrate the
easibility and potential advantages of targeted TBI
sing HT. Compared with conventional TBI, TMI
nd TMLI treatment plans using the same total dose
esulted in substantially lower median doses to all
ajor organs. DVHs demonstrated reduced doses to
lmost the entire volume of each organ. These data
redict that treatment-related morbidity will be sig-
iﬁcantly reduced with this form of targeted TBI,
roviding a compelling reason to evaluate this strategy
s part of myeloablative conditioning regimens. For
xample, DVH dosimetric analysis demonstrated that
ung doses were substantially lower for TMI than for
onventional TBI, predicting for the ability to escalate
he TMI dose to 20 Gy without incurring any addi-
ional risk of pneumonitis.
The 53-year-old patient with multiple myeloma
eported here represents the ﬁrst case treated with
MI using HT (TomoTherapy, personal communi-
ation). Multiple myeloma presents an appropriate
linical setting to begin evaluation of this novel form
f targeted TBI. Attempts to improve overall response
nd response duration have focused on using myeloa-
lative therapies [27]. Conventional TBI has been part
f these strategies, but it results in signiﬁcant side
ffects when combined with high-dose chemotherapy
28]. A more targeted TBI strategy is needed to reduce
ssociated side effects, thereby permitting dose esca-
ation in this highly radiosensitive disease.
Results from this ﬁrst case demonstrate the feasi-
ility of using HT to deliver targeted TBI and con-
rms the ability of HT to deliver a myeloablative dose
electively to skeletal bone and bone marrow. Organ
oses were comparable to those from the initial pre-
linical studies and predicted reduced toxicities com-
ared with standard TBI. Although more patients and
onger follow-up are needed, the fact that the ﬁrst
atient experienced minimal nausea and vomiting and
o diarrhea, skin erythema, mucositis, or esophagitis
hile still achieving the expected count nadirs is very
ncouraging.
Other potential advantages of this approach are
lso evident from this study. The total dose to each
ompartment can be individualized, with a given or-
an compartment or target region receiving a mini-
um dose, a partial dose, or a maximum tolerated
ose. For example, areas of recurrent or residual dis-
ase that may be resistant to chemotherapy can receive
simultaneous boosted dose with TMI or TMLI;
anctuary sites, such as the central nervous system, can
e selectively targeted; and areas that were previously
rradiated can be outlined and the dose minimized or c
B&MTnly a partial dose delivered while the rest of the
arget region receives the intended full dose.
Some questions are not addressed by the results of
his study and can be evaluated only through clinical
rials. The TMI and TMLI treatment strategies pre-
ented in this report deliver the full dose to a user-
eﬁned anatomic target region felt to harbor a signif-
cant percentage of the tumor burden. In addition,
ith TMLI, major lymphoid regions are targeted to
rovide sufﬁcient immunosuppression in the allograft
etting. However, unlike conventional TBI, these tar-
eted TBI approaches deliver reduced doses (approx-
mately 1.7- to 7.5-fold less) to malignant cells that are
n circulation or lie outside the deﬁned target region.
his may result in an increase in relapse rate [29].
owever, this possible disadvantage may be out-
eighed by the potential advantage of intensifying
ystemic chemotherapy delivered with targeted TBI
ecause of reduced radiation-related side effects.
Targeted TBI can potentially reduce acute graft-
ersus-host disease in the allogeneic transplantation
etting, which some feel is triggered by normal tissue
amage and induction of inﬂammatory cytokines set
nto play from dose-intensive conditioning regimens.
lthough this should translate into reduced treat-
ent-related morbidity and mortality, there could
lso be a second-order effect from decreased graft-
ersus-disease effects. The ultimate impact of this
ariable on overall survival and outcome remains to be
etermined.
The importance of the higher radiation dose rate
n HT compared with conventional TBI is unknown.
nstantaneous dose rates for conventional TBI range
rom approximately 4 to 20 cGy/minute, compared to
maximum of 8 Gy/minute for HT TMI. The full
mpact of dose rate on marrow stroma and engraft-
ent remains to be determined, although the patient
eported here demonstrated no problems with en-
raftment.
Other methods of targeted TBI, including bone-
eeking radionuclide therapy and antibody-guided ra-
iation therapy (or radioimmunotherapy), are being
ctively evaluated in clinical trials as part of condition-
ng regimens for patients undergoing transplantation.
linical results using these biologically targeted forms
f TBI are encouraging, but also demonstrate several
otential limitations. Tumor doses from radiolabeled
ntibodies are generally lower than can be achieved
ith targeted external-beam radiotherapy, with me-
ian or mean doses ranging from 240 to 1700 cGy at
onmyeloablative-administered activities [30]. Even at
yeloablative administered activities, the estimated
oses to marrow are lower than those achievable by
argeted TMI or TMLI. In addition, interpatient and
ntrapatient variation of doses to tumor sites and normal
rgans exist because of individual variations in antibody
learance rates and biodistribution that cannot be easily
313
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3ontrolled for. Finally, normal organ uptake and clear-
nce of these agents can result in radiation-induced tox-
cities [31-33]. These factors are not seen with TMI or
MLI.
But rather than competing strategies, these differ-
nt forms of targeted TBI may be best used in com-
ination, because each complements the other. HT-
argeted TBI has the potential to deliver additional
oses to tumor sites and to create dose- avoidance re-
ions where needed, with the dose and dose regions
otentially tailored to complement the unique radionu-
lide dose distribution of a given patient. HT-targeted
BI can also deliver additional dose to sanctuary sites
ikely underdosed by systemically administered radionu-
lide. Finally, systemic-targeted radionuclide therapy,
uch as radioimmunotherapy, complements HT-tar-
eted TBI by targeting the dose to malignant cells in
irculation that are not treated to full dose with HT.
ombination targeted TBI strategies will likely prove
easible, because several trials that have combined
onventional TBI and radioimmunotherapy have dem-
nstrated engraftment with cumulative marrow doses
f up to approximately 40 Gy [34].
In summary,results from this study demonstrate
he feasibility and potential advantages to selectively
eliver myeloablative doses of radiation to bone and
arrow using an image-guided tomographic intensity-
odulated radiation therapy delivery system. Organ
oses are substantially lower than those associated
ith standard TBI and predict the potential to signif-
cantly reduce associated toxicities and allow for dose
scalation. Given the available data, it is likely that
here will be further room for dose escalation to the
one marrow before nonengraftment is observed. Re-
ults also suggest that this form of targeted TBI may
ave potential advantages over other forms of targeted
BI, such as radioimmunotherapy or bone-seeking
adionuclide therapy. Clinical trials are currently un-
erway to deﬁne the maximum TMI and TMLI doses
chievable, characterize associated toxicities, and de-
ne the potential advantages and limitations of this
ew approach for patients undergoing hematopoietic
tem cell transplantation.
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